McKnight A J, Woodman A M, Parkkonen M, Patterson C C, Savage D A, Forsblom C, Pettigrew K A, Sadlier D, Groop P H, Maxwell A P
Nephrology Research Group, Queen's University of Belfast, c/o Regional Genetics Centre, Belfast City Hospital, Belfast, Northern Ireland, UK.
Diabetologia. 2009 May;52(5):844-9. doi: 10.1007/s00125-009-1281-3. Epub 2009 Feb 27.
AIMS/HYPOTHESIS: SMAD proteins are involved in multiple signalling pathways and are key modulators of gene expression. We hypothesised that genetic variation in selected SMAD genes contributes to susceptibility to diabetic nephropathy.
We selected 13 haplotype tag (ht) single nucleotide polymorphisms (SNPs) from 67 variants identified by resequencing the SMAD2 and SMAD3 genes. For SMAD1, SMAD4 and SMAD5 genes, genotype data were downloaded for 217 SNPs from Phase II of the International HapMap project. Of these, 85 SNPs met our inclusion criteria, resulting in the selection of 13 tag SNPs for further investigation. A case-control approach was employed, using 267 nephropathic patients and 442 controls with type 1 diabetes from Ireland. Two further populations (totalling 1,407 patients, 2,238 controls) were genotyped to validate initial findings. Genotyping was conducted using iPLEX, TaqMan and gel electrophoresis.
The distribution of genotypes was in Hardy-Weinberg equilibrium. Analysis by the chi(2) test of genotype and allele frequencies in patients versus controls in the Irish population (n = 709) revealed evidence for the association of one allele at 5% level of significance (rs10515478, p(uncorrected) = 0.006; p(corrected) = 0.04). This finding represents a relatively small difference in allele frequency of 6.4% in the patient group compared with 10.7% in the control group; this difference was not supported in subsequent investigations using DNA from European individuals with similar phenotypic characteristics.
CONCLUSIONS/INTERPRETATION: We selected an appropriate subset of variants for the investigation of common genetic risk factors and assessed SMAD1 to SMAD5 genes for association with diabetic nephropathy. We conclude that common polymorphisms in these genes do not strongly influence genetic susceptibility to diabetic nephropathy in white individuals with type 1 diabetes mellitus.
目的/假设:SMAD蛋白参与多种信号通路,是基因表达的关键调节因子。我们推测,选定的SMAD基因中的遗传变异会导致糖尿病肾病易感性增加。
我们从通过对SMAD2和SMAD3基因进行重测序鉴定出的67个变异中选择了13个单倍型标签(ht)单核苷酸多态性(SNP)。对于SMAD1、SMAD4和SMAD5基因,从国际HapMap项目第二阶段下载了217个SNP的基因型数据。其中,85个SNP符合我们的纳入标准,从而选择了13个标签SNP进行进一步研究。采用病例对照研究方法,使用来自爱尔兰的267例肾病患者和442例1型糖尿病对照。另外两个群体(共1407例患者,2238例对照)进行基因分型以验证初步结果。基因分型采用iPLEX、TaqMan和凝胶电泳进行。
基因型分布符合哈迪-温伯格平衡。对爱尔兰人群(n = 709)中的患者与对照的基因型和等位基因频率进行卡方检验分析,结果显示有一个等位基因在5%的显著性水平上存在关联(rs10515478,p(未校正)= 0.006;p(校正)= 0.04)。这一发现表明患者组与对照组的等位基因频率相对差异较小,分别为6.4%和10.7%;在随后对具有相似表型特征的欧洲个体进行的DNA研究中,这一差异未得到证实。
结论/解读:我们选择了合适的变异子集来研究常见遗传风险因素,并评估了SMAD1至SMAD5基因与糖尿病肾病的关联。我们得出结论,这些基因中的常见多态性对1型糖尿病白人个体的糖尿病肾病遗传易感性没有强烈影响。